Alnylam Pharmaceuticals: Building Value from the IP Estate (B)

內容大綱
The leader of a pioneering biotech company in the siRNA space weighs his options for scaling production capacity in advance of an anticipated commercial launch. Operational complexity and relative merits of in-house manufacturing versus a contractor model are discussed.
涵蓋主題
新增
新增